Barclays PLC Clearside Biomedical, Inc. Transaction History

Barclays PLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.35 - $2.88 $675 - $1,440	-500 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.72 - $5.72 $45,010 - $94,654	-16,548 Reduced 97.07%	500 $1,000
Q3 2021 Nov 09, 2021	BUY	$4.83 - $7.2 $82,341 - $122,745	17,048 New	17,048 $102,000
Q2 2021 Aug 13, 2021	SELL	$2.32 - $5.38 $39,544 - $91,702	-17,045 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$2.24 - $4.25 $38,180 - $72,441	17,045 New	17,045 $42,000
Q1 2020 May 13, 2020	SELL	$1.32 - $3.77 $1 - $3	-1 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$0.62 - $3.4 $2 - $13	-4 Reduced 80.0%	1 $0
Q3 2019 Nov 14, 2019	SELL	$0.59 - $1.32 $21,460 - $48,012	-36,373 Reduced 99.99%	5 $0
Q2 2019 Aug 14, 2019	BUY	$0.97 - $1.42 $27,165 - $39,768	28,006 Added 334.52%	36,378 $35,000
Q1 2019 May 15, 2019	BUY	$1.1 - $1.74 $5,704 - $9,023	5,186 Added 162.77%	8,372 $12,000
Q4 2018 Feb 14, 2019	SELL	$1.0 - $6.12 $16,718 - $102,314	-16,718 Reduced 83.99%	3,186 $3,000
Q3 2018 Nov 14, 2018	BUY	$6.03 - $11.24 $80,741 - $150,503	13,390 Added 205.56%	19,904 $122,000
Q2 2018 Aug 14, 2018	SELL	$8.91 - $14.54 $10,166 - $16,590	-1,141 Reduced 14.91%	6,514 $70,000
Q1 2018 May 15, 2018	BUY	$5.57 - $14.28 $23,705 - $60,775	4,256 Added 125.21%	7,655 $82,000
Q4 2017 Feb 14, 2018	BUY	$5.78 - $9.12 $16,877 - $26,630	2,920 Added 609.6%	3,399 $24,000
Q3 2017 Nov 14, 2017	BUY	$6.73 - $8.74 $3,223 - $4,186	479	479 $4,000

12.2M

54.7K

50.7K

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $52.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.